| Reaction Details |
|---|
 | Report a problem with these data |
| Target | C-C chemokine receptor type 1 |
|---|
| Ligand | BDBM50056466 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1452284 (CHEMBL3366538) |
|---|
| IC50 | 3.0±n/a nM |
|---|
| Citation |  Santella, JB; Gardner, DS; Duncia, JV; Wu, H; Dhar, M; Cavallaro, C; Tebben, AJ; Carter, PH; Barrish, JC; Yarde, M; Briceno, SW; Cvijic, ME; Grafstrom, RR; Liu, R; Patel, SR; Watson, AJ; Yang, G; Rose, AV; Vickery, RD; Caceres-Cortes, J; Caporuscio, C; Camac, DM; Khan, JA; An, Y; Foster, WR; Davies, P; Hynes, J Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem57:7550-64 (2014) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| C-C chemokine receptor type 1 |
|---|
| Name: | C-C chemokine receptor type 1 |
|---|
| Synonyms: | C-C CKR-1 | C-C chemokine receptor type 1 (CCR1) | CC-CKR-1 | CCR-1 | CCR1 | CCR1_HUMAN | CD_antigen=CD191 | CMKBR1 | CMKR1 | HM145 | LD78 receptor | MIP-1alpha-R | Macrophage inflammatory protein 1-alpha receptor | RANTES-R | SCYAR1 |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 41180.69 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P32246 |
|---|
| Residue: | 355 |
|---|
| Sequence: | METPNTTEDYDTTTEFDYGDATPCQKVNERAFGAQLLPPLYSLVFVIGLVGNILVVLVLV
QYKRLKNMTSIYLLNLAISDLLFLFTLPFWIDYKLKDDWVFGDAMCKILSGFYYTGLYSE
IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIIIWALAILASMPGLYFSKTQWEFTH
HTCSLHFPHESLREWKLFQALKLNLFGLVLPLLVMIICYTGIIKILLRRPNEKKSKAVRL
IFVIMIIFFLFWTPYNLTILISVFQDFLFTHECEQSRHLDLAVQVTEVIAYTHCCVNPVI
YAFVGERFRKYLRQLFHRRVAVHLVKWLPFLSVDRLERVSSTSPSTGEHELSAGF
|
|
|
|---|
| BDBM50056466 |
|---|
| n/a |
|---|
| Name | BDBM50056466 |
|---|
| Synonyms: | CHEMBL3334727 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C24H36ClN3O4 |
|---|
| Mol. Mass. | 466.013 |
|---|
| SMILES | CC(C)[C@@H](NC(=O)N[C@H]1CC[C@H](O)C1)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
